Sutro Financial Statements From 2010 to 2025

STRO Stock

USD 0.78 0.01 1.30%

Sutro Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sutro Biopharma's valuation are provided below:

Gross Profit

120.9 M

Profit Margin

(2.00)

Market Capitalization

66.1 M

Enterprise Value Revenue

0.3577

Revenue

104.5 M

We have found one hundred twenty available fundamental trend indicators for Sutro Biopharma, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Sutro Biopharma's current fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 15th of August 2025, Market Cap is likely to grow to about 252.2 M, though Enterprise Value is likely to grow to (24.5 M).

Sutro Biopharma Total Revenue

70.98 Million

Check Sutro Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sutro Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 14 M, Interest Income of 46.6 M or Depreciation And Amortization of 6.3 M, as well as many indicators such as Price To Sales Ratio of 4.54, Dividend Yield of 0.0 or PTB Ratio of 3.33. Sutro financial statements analysis is a perfect complement when working with Sutro Biopharma Valuation or Volatility modules.

Build AI portfolio with Sutro Stock

Check out the analysis of Sutro Biopharma Correlation against competitors.

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

Sutro Biopharma Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

304.3 M

387.2 M

200.6 M

Slightly volatile

Short and Long Term Debt Total

29.3 M

23.2 M

17.3 M

Slightly volatile

Other Current Liabilities

38.5 M

36.7 M

12.6 M

Slightly volatile

Total Current Liabilities

138.5 M

131.9 M

59.7 M

Slightly volatile

Other Liabilities

108.7 M

103.5 M

32.5 M

Slightly volatile

Property Plant And Equipment Net

30.5 M

35.9 M

24.5 M

Slightly volatile

Current Deferred Revenue

73.3 M

69.8 M

34.8 M

Very volatile

Accounts Payable

6.3 M

10.5 M

4.9 M

Slightly volatile

Cash

199.8 M

190.3 M

61 M

Slightly volatile

Non Current Assets Total

49.5 M

43.9 M

35.8 M

Slightly volatile

Non Currrent Assets Other

12.5 M

8 M

7.3 M

Slightly volatile

Other Assets

3 M

3.1 M

9.4 M

Pretty Stable

Long Term Debt

4.1 M

4.3 M

5.3 M

Slightly volatile

Cash And Short Term Investments

242.6 M

316.9 M

157 M

Slightly volatile

Net Receivables

9.9 M

8.6 M

5.9 M

Slightly volatile

Common Stock Shares Outstanding

39.1 M

76.8 M

22.6 M

Slightly volatile

Long Term Debt Total

11.4 M

18.1 M

8.1 M

Slightly volatile

Liabilities And Stockholders Equity

304.3 M

387.2 M

200.6 M

Slightly volatile

Non Current Liabilities Total

116.1 M

210.7 M

107.9 M

Pretty Stable

Capital Surpluse

707.9 M

674.2 M

269.7 M

Slightly volatile

Total Liabilities

179 M

342.6 M

162.8 M

Slightly volatile

Property Plant And Equipment Gross

45.7 M

84.5 M

33.2 M

Slightly volatile

Preferred Stock Total Equity

82 M

92.3 M

100.6 M

Slightly volatile

Total Current Assets

254.8 M

343.3 M

164.9 M

Slightly volatile

Non Current Liabilities Other

2 M

1.9 M

461 K

Slightly volatile

Short Term Debt

10.4 M

15 M

7.2 M

Slightly volatile

Common Stock

45.6 K

83 K

32.2 K

Slightly volatile

Property Plant Equipment

61.7 M

58.7 M

28.3 M

Slightly volatile

Deferred Long Term Liabilities

1.6 M

1.5 M

837.8 K

Slightly volatile

Short and Long Term Debt

6.2 M

3.7 M

10.5 M

Slightly volatile

Common Stock Total Equity

38 K

52.9 K

31.6 K

Slightly volatile

Capital Stock

53.4 K

83 K

36.1 K

Slightly volatile

Sutro Biopharma Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Interest Income

46.6 M

44.4 M

7.3 M

Slightly volatile

Depreciation And Amortization

6.3 M

7.2 M

5.7 M

Slightly volatile

Selling General Administrative

42.6 M

48.5 M

30 M

Slightly volatile

Total Revenue

71 M

62 M

63.1 M

Slightly volatile

Other Operating Expenses

161 M

300.5 M

114.3 M

Slightly volatile

Research Development

264.6 M

252 M

93.4 M

Slightly volatile

Cost Of Revenue

6.9 M

7.2 M

37 M

Slightly volatile

Total Operating Expenses

157.1 M

293.3 M

112.1 M

Slightly volatile

Income Tax Expense

2.2 M

2.4 M

2.9 M

Slightly volatile

Reconciled Depreciation

5.9 M

7.2 M

5.2 M

Slightly volatile

Selling And Marketing Expenses

5.5 M

6.1 M

6.7 M

Slightly volatile

Sutro Biopharma Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

15.5 M

24.7 M

9.2 M

Slightly volatile

Begin Period Cash Flow

65.5 M

70.1 M

43.3 M

Slightly volatile

Depreciation

6 M

7.2 M

5.5 M

Pretty Stable

Capital Expenditures

6.2 M

3.1 M

5.2 M

Slightly volatile

End Period Cash Flow

200.7 M

191.2 M

61.5 M

Slightly volatile

Issuance Of Capital Stock

94.6 M

96.5 M

142.3 M

Slightly volatile

Dividends Paid

393.8 K

532.5 K

350 K

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

4.54

2.2785

3.5192

Slightly volatile

Days Sales Outstanding

34.5

50.6881

27.7333

Slightly volatile

Stock Based Compensation To Revenue

0.42

0.3979

0.1549

Slightly volatile

Capex To Depreciation

0.41

0.4292

0.9278

Pretty Stable

Payables Turnover

0.65

0.6891

9.7798

Slightly volatile

Sales General And Administrative To Revenue

0.51

0.781

0.4822

Slightly volatile

Research And Ddevelopement To Revenue

4.27

4.0624

1.5079

Slightly volatile

Capex To Revenue

0.0772

0.0499

0.0867

Pretty Stable

Cash Per Share

3.92

4.1247

50.4785

Slightly volatile

Days Payables Outstanding

556

530

145

Slightly volatile

Current Ratio

3.66

2.6029

3.1763

Slightly volatile

Receivables Turnover

6.84

7.2009

51.1995

Slightly volatile

Capex Per Share

0.0383

0.0403

4.454

Slightly volatile

Revenue Per Share

0.77

0.8075

60.4211

Slightly volatile

Interest Debt Per Share

1.36

0.7058

1.7949

Slightly volatile

Debt To Assets

0.0568

0.0598

0.0719

Slightly volatile

Days Of Payables Outstanding

556

530

145

Slightly volatile

Ebt Per Ebit

1.05

0.944

1.0703

Slightly volatile

Long Term Debt To Capitalization

0.84

0.8021

0.1878

Slightly volatile

Quick Ratio

3.68

2.6029

3.1885

Slightly volatile

Net Income Per E B T

1.19

1.0105

1.0428

Slightly volatile

Cash Ratio

1.34

1.4429

1.1139

Slightly volatile

Days Of Sales Outstanding

34.5

50.6881

27.7333

Slightly volatile

Fixed Asset Turnover

3.16

1.7298

3.0108

Slightly volatile

Debt Ratio

0.0568

0.0598

0.0719

Slightly volatile

Price Sales Ratio

4.54

2.2785

3.5192

Slightly volatile

Asset Turnover

0.15

0.1602

0.5527

Slightly volatile

Sutro Biopharma Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

252.2 M

141.4 M

220.1 M

Slightly volatile

Sutro Fundamental Market Drivers

Cash And Short Term Investments

316.9 M

Sutro Upcoming Events

	4th of April 2024 Upcoming Quarterly Report	View
	20th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	4th of April 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Sutro Biopharma Financial Statements

Sutro Biopharma investors utilize fundamental indicators, such as revenue or net income, to predict how Sutro Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	69.8 M	73.3 M
Total Revenue	62 M	71 M
Cost Of Revenue	7.2 M	6.9 M
Stock Based Compensation To Revenue	0.40	0.42
Sales General And Administrative To Revenue	0.78	0.51
Research And Ddevelopement To Revenue	4.06	4.27
Capex To Revenue	0.05	0.08
Revenue Per Share	0.81	0.77
Ebit Per Revenue	(3.84)	(3.65)

Pair Trading with Sutro Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Sutro Stock

0.45	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.41	A	Agilent Technologies Earnings Call This Week	Pair Corr
0.38	SABSW	SAB Biotherapeutics	Pair Corr
0.36	MRK	Merck Company Aggressive Push	Pair Corr
0.35	EDIT	Editas Medicine	Pair Corr

The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.

The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Sutro Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sutro Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sutro Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sutro Biopharma Stock:

How To Invest In Sutro

Details

Is Sutro Stock a good investment?

Details

What is Sutro Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Sutro Biopharma Correlation against competitors.

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.51)

Revenue Per Share

1.257

Quarterly Revenue Growth

1.48

Return On Assets

(0.28)

Return On Equity

(3.48)

The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Sutro Financial Statements From 2010 to 2025

Sutro Biopharma Total Revenue

70.98 Million

Sutro Biopharma Balance Sheet

Sutro Biopharma Income Statement

Sutro Biopharma Cash Flow Statement

Financial Ratios

Sutro Biopharma Valuation Data

Sutro Fundamental Market Drivers

Sutro Upcoming Events

About Sutro Biopharma Financial Statements

Pair Trading with Sutro Biopharma

Moving against Sutro Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY